Shenzhen Salubris Pharmaceuticals Co.Ltd(002294) (002294) on January 3, it was announced that the market space outside the centralized procurement had shrunk significantly because some hospitals at all levels in provinces and cities basically purchased all the winning supports for centralized procurement; At the same time, the repeated and sporadic outbreaks of local epidemics make the amount of elective surgery lower than expected, and it is expected that Huanchen’s profitability will still be adversely affected in the future. In the fourth quarter of 2021, the company made an impairment provision of 121 million yuan for the intangible assets of Huanchen asset group. In addition, the application for listing of ennastat tablets submitted by the company recently was accepted by the State Food and drug administration.
(Securities Times)
